Kevin Foster

Prof. Kevin Foster


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Burns
Verified
Journal Article
Open access
JHJ.H. Holmes
J.H. Holmes
JMJ.A. Molnar
J.A. Molnar
JSJ.W. Shupp
J.W. Shupp
WHW.L. Hickerson
W.L. Hickerson
BKBooker T. King
Booker T. King
JCJ.E. Carter
J.E. Carter
Split-thickness skin grafts (STSG) are the standard of care (SOC) for burns undergoing autografting but are associated with donor skin site morbidity and limited by the availability of uninjured skin. The RECELL® Autologous Cell Harvesting Device (RECELL® System, or RECELL) was developed for point-of-care preparation and application of a suspension of non-cultured, disaggregated, autologous skin cells, using 1cm2 of the patient's skin to treat up to 80cm2 of excised burn. A multi-center, prospective, within-subject controlled, randomized, clinical trial was conducted with 30 subjects to evaluate RECELL in combination with a more widely meshed STSG than a pre-defined SOC meshed STSG (RECELL treatment) for the treatment of mixed-depth burns, including full-thickness. Treatment areas were randomized to receive standard meshed STSG (Control treatment) or RECELL treatment, such that each subject had 1 Control and 1 RECELL treatment area. Effectiveness measures were assessed and included complete wound closure, donor skin use, subject satisfaction, and scarring outcomes out to one year following treatment. At 8 weeks, 85% of the Control-treated wounds were healed compared with 92% of the RECELL-treated wounds, establishing the non-inferiority of RECELL treatment for wound healing. Control-treated and RECELL-treated wounds were similar in mean size; however, mean donor skin use was significantly reduced by 32% with the use of RECELL (p<0.001), establishing the superiority of RECELL treatment for reducing donor skin requirements. Secondary effectiveness and safety outcomes were similar between the treatments. In combination with widely meshed STSG, RECELL is a safe and effective point-of-care treatment for mixed-depth burns without confluent dermis, achieving short- and long-term healing comparable to standard STSG, while significantly decreasing donor skin use.

1 November 2001 in Journal of Burn Care & Rehabilitation
Verified
Journal Article
Closed access
RMR. Mann
R. Mann
Nicole S. GibranNicole S. Gibran
Nicole S. Gibran
LEL. H. Engrav
L. H. Engrav
KFKevin Foster
Kevin Foster
NMN. A. Meyer
N. A. Meyer
DHD. M. Heimbach
D. M. Heimbach
For best function and appearance, thick skin grafts for hands are generally preferred to thinner grafts. But how thick is thick enough? This prospective randomized trial was designed to compare 0.015-inch skin grafts for burned hands to hand grafts that are 0.025 inches thick. Consecutive patients receiving skin grafts to hands were randomized to have sheet grafts using donor sites of 0.015-inch or 0.025-inch thickness. To prevent delayed healing and potential hypertrophic scarring, the thick graft donor sites were grafted with 0.008-inch grafts. There were no significant differences in range of motion, final appearance, or patient satisfaction between the two groups at 1 year. There were problems with donor site healing in both groups. We recommend that hand grafts for adults be at least 0.015 inches thick but do not see an advantage to the use of very thick (0.025-inch) grafts, even with thin split-thickness skin grafts to the donor site.

1 January 2014 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
KFKevin Foster
Kevin Foster
A clinical guideline (CG) is best defined as “systematically developed statements to assist health care professional and patient decision making about appropria

1 November 2010 in Journal of Surgical Education
Verified
Journal Article
Closed access
FSFariha Sheikh
Fariha Sheikh
RGRichard J. Gray
Richard J. Gray
JFJohn Ferrara
John Ferrara
KFKevin Foster
Kevin Foster
ACAlyssa Chapital
Alyssa Chapital

1 September 2023 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Open access
SHSharon Henry
Sharon Henry
SMSteven Mapula
Steven Mapula
MGMark Grevious
Mark Grevious
KFKevin Foster
Kevin Foster
HPHerbert Phelan
Herbert Phelan
JMJoseph A. Molnar
Joseph A. Molnar
BACKGROUND: Traumatic insults, infection, and surgical procedures can leave skin defects that are not amenable to primary closure. Split-thickness skin grafting (STSG) is frequently used to achieve closure of these wounds. Although effective, STSG can be associated with donor site morbidity, compounding the burden of illness in patients undergoing soft tissue reconstruction procedures. With an expansion ratio of 1:80, autologous skin cell suspension (ASCS) has been demonstrated to significantly decrease donor skin requirements compared with traditional STSG in burn injuries. We hypothesized that the clinical performance of ASCS would be similar for soft tissue reconstruction of nonburn wounds. METHODS: A multicenter, within-patient, evaluator-blinded, randomized-controlled trial was conducted of 65 patients with acute, nonthermal, full-thickness skin defects requiring autografting. For each patient, two treatment areas were randomly assigned to concurrently receive a predefined standard-of-care meshed STSG (control) or ASCS + more widely meshed STSG (ASCS+STSG). Coprimary endpoints were noninferiority of ASCS+STSG for complete treatment area closure by Week 8, and superiority for relative reduction in donor skin area. RESULTS: At 8 weeks, complete closure was observed for 58% of control areas compared with 65% of ASCS+STSG areas (p = 0.005), establishing noninferiority of ASCS+STSG. On average, 27.4% less donor skin was required with ASCS+ STSG, establishing superiority over control (p < 0.001). Clinical healing (≥95% reepithelialization) was achieved in 87% and 85% of Control and ASCS+STSG areas, respectively, at 8 weeks. The treatment approaches had similar long-term scarring outcomes and safety profiles, with no unanticipated events and no serious ASCS device-related events. CONCLUSION: ASCS+STSG represents a clinically effective and safe solution to reduce the amount of skin required to achieve definitive closure of full-thickness defects without compromising healing, scarring, or safety outcomes. This can lead to reduced donor site morbidity and potentially decreased cost associated with patient care. Clincaltrials.gov identifier: NCT04091672 LEVEL OF EVIDENCE: Therapeutic/Care Management; Level I.

1 March 2019 in Burns
Verified
Journal Article
Closed access
JSJacob A. Swann
Jacob A. Swann
MMMarc R. Matthews
Marc R. Matthews
CBCurt Bay
Curt Bay
KFKevin Foster
Kevin Foster